Johnson & Johnson (NYSE:JNJ) is Moody National Bank Trust Division’s 7th Largest Position

Moody National Bank Trust Division lowered its position in Johnson & Johnson (NYSE:JNJGet Rating) by 6.1% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 63,462 shares of the company’s stock after selling 4,156 shares during the period. Johnson & Johnson comprises about 1.2% of Moody National Bank Trust Division’s portfolio, making the stock its 7th largest holding. Moody National Bank Trust Division’s holdings in Johnson & Johnson were worth $11,266,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in JNJ. Family CFO Inc purchased a new stake in Johnson & Johnson during the fourth quarter worth about $26,000. RE Dickinson Investment Advisors LLC increased its holdings in Johnson & Johnson by 163.3% during the first quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock worth $28,000 after buying an additional 98 shares during the last quarter. Advanced Research Investment Solutions LLC increased its holdings in Johnson & Johnson by 200.0% during the first quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock worth $32,000 after buying an additional 120 shares during the last quarter. Professional Financial Advisors LLC increased its holdings in Johnson & Johnson by 47.9% during the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock worth $37,000 after buying an additional 68 shares during the last quarter. Finally, Joseph P. Lucia & Associates LLC purchased a new stake in Johnson & Johnson during the first quarter worth about $38,000. Hedge funds and other institutional investors own 68.59% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on JNJ. UBS Group decreased their price objective on shares of Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Daiwa Capital Markets assumed coverage on shares of Johnson & Johnson in a research note on Wednesday, June 22nd. They issued an “outperform” rating for the company. SVB Leerink reduced their target price on shares of Johnson & Johnson from $200.00 to $194.00 in a research note on Wednesday, July 20th. Morgan Stanley reduced their target price on shares of Johnson & Johnson from $174.00 to $173.00 and set an “equal weight” rating for the company in a research note on Monday, September 12th. Finally, Citigroup reduced their target price on shares of Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday, July 20th. Four investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $189.78.

Johnson & Johnson Price Performance

JNJ stock opened at $167.60 on Friday. The firm has a 50 day moving average of $168.96 and a 200-day moving average of $174.23. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The firm has a market capitalization of $440.65 billion, a P/E ratio of 24.40, a price-to-earnings-growth ratio of 2.95 and a beta of 0.61.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The business had revenue of $24.02 billion during the quarter, compared to analyst estimates of $23.85 billion. During the same period in the previous year, the business posted $2.48 earnings per share. Johnson & Johnson’s revenue for the quarter was up 3.0% on a year-over-year basis. As a group, sell-side analysts predict that Johnson & Johnson will post 10.7 earnings per share for the current fiscal year.

Johnson & Johnson announced that its Board of Directors has initiated a stock repurchase plan on Wednesday, September 14th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the company to repurchase up to 1.2% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board of directors believes its stock is undervalued.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd were given a dividend of $1.13 per share. The ex-dividend date of this dividend was Monday, August 22nd. This represents a $4.52 annualized dividend and a yield of 2.70%. Johnson & Johnson’s payout ratio is presently 65.79%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.